Quhuo Reports Financial Results for the Second Half and Full Year 2024
BEIJING, April 29, 2025 /PRNewswire/ -- Quhuo Limited (Nasdaq: QH) ("Quhuo," the "Company," "we" or "our"), a leading gig economy platform focusing on local life services in China, today reported its unaudited financial results for the six months...
Sonitus Medical and BHM Establish Strategic Cooperation
SHANGHAI, April 28, 2025 /PRNewswire/ -- Sonitus Medical has entered into a strategic cooperation with BHM, a renowned European manufacturer of bone conduction hearing devices. The two companies will engage in deep collaboration across product...
GENE SOLUTIONS AND ELEMENT BIOSCIENCES ENTER STRATEGIC COLLABORATION TO ADVANCE NEXT-GENERATION SEQUENCING (NGS) TECHNOLOGY GLOBALLY
HO CHI MINH CITY, April 22, 2025 /PRNewswire/ -- Gene Solutions, a leading multinational biotech company specializing in advanced genetic testing, and Element Biosciences, a company democratizing access to advanced life science solutions, have...
AB Crosses the Singularity: Building a New Generation of Secure and Scalable Infrastructure for Decentralized Applications and Assets
SINGAPORE, April 8, 2025 /PRNewswire/ -- In early April, at a bustling Web3 gathering in Hong Kong, a crypto investor from Dubai named Ahmed shared a story that captured the attention of the room. "When I recovered my three-year-old BEP2 tokens...
TCTM Announces Entering into An Intangible Asset Purchase Agreement
BEIJING, April 7, 2025 /PRNewswire/ -- TCTM Kids IT Education Inc. (NASDAQ: TCTM) ("TCTM" or the "Company"), a leading provider of IT-focused supplementary STEM education services in China, today announced that it has entered into an intangible...
Akeso's 2024 Results: Strengthening Global Competitiveness and Transforming the Treatment Landscape with Bispecific Antibodies
Key Highlights: Global first "immuno + anti-vascular" bispecific antibody approved: ivonescimab for EGFR-TKI resistant nsq-NSCLC. Phase III HARMONi study topline data expected mid-2025 (FDA FTD). ivonescimab outperforms pembrolizumab in Phase III...
AnHorn Medicines Announces First Subject Dosed in AH-001 Phase I Clinical Trial in the United States
TAIPEI, March 27, 2025 /PRNewswire/ -- AnHorn Medicines, a pioneering AI-driven new drug discovery company, is pleased to announce that, AH-001, a first-in-class protein degrader for androgenetic alopecia (AGA), has officially entered Phase I...
Europe Becomes a New Strategic Hub for ChangAn Automobile's "Vast Ocean Plan" as Global Growth Accelerates
Review of the Globalization Journey of the Vast Ocean Plan MUNICH, March 24, 2025 /PRNewswire/ -- ChangAn Automobile ("ChangAn" or "the Company"), an intelligent low-carbon mobility technology company, launched its CHANG-AN, DEEPAL, and AVATR brands...
FlexFuel Hydrogen Development (Shenzhen) has entered into a landmark Strategic Collaboration Agreement with MCC Tiangong Group Corporation Limited
Committed to advancing green energy solutions Capitalizing on growing opportunities in the hydrogen technology sector HONG KONG, March 21, 2025 /PRNewswire/ -- China International Development Corporation Limited ("CIDC" or the "Company", together...
China Merchants Commercial REIT Reports Total Revenue of RMB529 Million in 2024; Occupancy Rate at Garden City Shopping Centre in Shenzhen Surges Significantly; Overall Operational Performance Continues to Optimize
HONG KONG, March 18, 2025 /PRNewswire/ -- China Merchants Commercial Real Estate Investment Trust ("CMC REIT" or "the Trust", HKEX stock code:1503), announced its annual results for the year ended 31 December 2024. During the year, total revenue was...